Contra-indicated in patients with congenital long QT syndrome.
- TRADE NAME: Caprelsa (AstraZeneca)
- INDICATIONS: Medullary thyroid cancer
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 19 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amoxapine, Antiarrhythmics, Arsenic, Carbamazepine, Chloroquine, Clarithromycin, CYP3A4 inducers, Dexamethasone, Disopyramide, Dofetilide, Dolasetron, Efavirenz, Granisetron, Haloperidol, Methadone, Moxifloxacin, Pazopanib, Phenobarbital, Phenytoin, Pimozide, Procainamide, QT prolonging agents, Rifabutin, Rifampin, Rifapentine, Sotalol, St John's Wort, Telavancin
QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of vandetanib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/25/2025
